<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="69812"><DrugName>PEG-bHb-CO (sickle cell anemia/leg ulcers), Prolong Pharmaceuticals</DrugName><DrugNamesKey><Name id="42944804">Sanguinate</Name></DrugNamesKey><DrugSynonyms><Name><Value>Sanguinate</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>PEGylated bovine hemoglobin-carbon monoxide (trauma/cardiovascular disease), Prolong Pharmaceuticals</Value></Name><Name><Value>PEG-bHb-CO (trauma/cardiovascular disease), Prolong Pharmaceuticals</Value></Name><Name><Value>oxygen transfer agent (trauma/cardiovascular disease), Prolong Pharmaceuticals</Value></Name><Name><Value>pegylated carboxyhemoglobin bovine</Value></Name><Name><Value>PEG-bHb-CO (sickle cell anemia/leg ulcers), Prolong Pharmaceuticals</Value></Name></DrugSynonyms><CompanyOriginator id="30600">Prolong Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company id="30600">Prolong Pharmaceuticals Inc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="30600" type="Company"><TargetEntity id="4296923987" type="organizationId">Prolong Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1636" type="ciIndication"><TargetEntity id="I67.82" type="ICD10"/><TargetEntity id="D002545" type="MeSH"/><TargetEntity id="-137109010" type="omicsDisease"/><TargetEntity id="91" type="siCondition"/></SourceEntity><SourceEntity id="2369" type="ciIndication"><TargetEntity id="D56.1" type="ICD10"/><TargetEntity id="282.44" type="ICD9"/><TargetEntity id="10043391" type="MEDDRA"/><TargetEntity id="D017086" type="MeSH"/><TargetEntity id="848" type="ORPHANET"/><TargetEntity id="-1527735319" type="omicsDisease"/><TargetEntity id="2426" type="siCondition"/></SourceEntity><SourceEntity id="2989" type="ciIndication"><TargetEntity id="T86.11" type="ICD10"/><TargetEntity id="10023439" type="MEDDRA"/><TargetEntity id="1136" type="siCondition"/></SourceEntity><SourceEntity id="303" type="ciIndication"><TargetEntity id="10040641" type="MEDDRA"/><TargetEntity id="D000755" type="MeSH"/><TargetEntity id="232" type="ORPHANET"/><TargetEntity id="-2067923175" type="omicsDisease"/><TargetEntity id="994" type="siCondition"/></SourceEntity><SourceEntity id="3096" type="ciIndication"><TargetEntity id="D007871" type="MeSH"/><TargetEntity id="-1106136632" type="omicsDisease"/><TargetEntity id="4609" type="siCondition"/></SourceEntity><SourceEntity id="57" type="ciIndication"><TargetEntity id="10007649" type="MEDDRA"/><TargetEntity id="D002318" type="MeSH"/><TargetEntity id="-1500764314" type="omicsDisease"/><TargetEntity id="182" type="siCondition"/></SourceEntity><SourceEntity id="748" type="ciIndication"><TargetEntity id="10022116" type="MEDDRA"/><TargetEntity id="1186" type="siCondition"/><TargetEntity id="1239" type="siCondition"/></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="303">Sickle cell anemia</Indication><Indication id="3096">Leg ulcer</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1636">Brain ischemia</Indication><Indication id="2369">Beta thalassemia</Indication><Indication id="2989">Kidney transplant rejection</Indication><Indication id="57">Cardiovascular disease</Indication><Indication id="748">Injury</Indication></IndicationsSecondary><ActionsPrimary><Action id="474">Hemoglobin modulator</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="388">Vasodilator</Action><Action id="5002">Blood substitute</Action></ActionsSecondary><Technologies><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="348">PEGylated formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="207">Protein conjugated</Technology></Technologies><EphmraCodes><Ephmra><Code>C</Code><Name>CARDIOVASCULAR SYSTEM</Name></Ephmra><Ephmra><Code>K3</Code><Name>WHOLE BLOOD AND PLASMA SUBSTITUTE SOLUTIONS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-08-06T11:44:58.000Z</LastModificationDate><ChangeDateLast>2018-08-07T00:00:00.000Z</ChangeDateLast><AddedDate>2011-01-26T14:59:30.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="30600" linkType="Company"&gt;Prolong Pharmaceuticals&lt;/ulink&gt; is developing PEGylated bovine hemoglobin-carbon monoxide (PEG-bHb-CO;  pegylated carboxyhemoglobin bovine) formulated in saline (Sanguinate), an oxygen transfer agent, for the potential iv treatment of sickle cell anemia and leg ulcers due to ischmia [&lt;ulink linkID="1139582" linkType="Reference"&gt;1139582&lt;/ulink&gt;], [&lt;ulink linkID="1163655" linkType="Reference"&gt;1163655&lt;/ulink&gt;], [&lt;ulink linkID="1208558" linkType="Reference"&gt;1208558&lt;/ulink&gt;], [&lt;ulink linkID="1438138" linkType="Reference"&gt;1438138&lt;/ulink&gt;], [&lt;ulink linkID="1481691" linkType="Reference"&gt;1481691&lt;/ulink&gt;],   [&lt;ulink linkID="1627683" linkType="Reference"&gt;1627683&lt;/ulink&gt;], [&lt;ulink linkID="1985950" linkType="Reference"&gt;1985950&lt;/ulink&gt;]. In July 2015, a phase II trial for sickle cell anemia was initiated  in the US; in December 2017, the trial was completed [&lt;ulink linkID="1649717" linkType="Reference"&gt;1649717&lt;/ulink&gt;].  In May 2017, preliminary data from the trial were presented. At that time, a phase II trial was planned for leg ulcers secondary to ischemia [&lt;ulink linkID="1923076" linkType="Reference"&gt;1923076&lt;/ulink&gt;]. In April 2015,  phase II trials were being planned for vaso-occlusive crisis and leg ulcers secondary to sickle cell [&lt;ulink linkID="1648510" linkType="Reference"&gt;1648510&lt;/ulink&gt;]; in December 2017, enrollment in the vaso-occlusive patients study was completed and data from ambulatory patients were presented [&lt;ulink linkID="1991336" linkType="Reference"&gt;1991336&lt;/ulink&gt;], [&lt;ulink linkID="1988987" linkType="Reference"&gt;1988987&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Prolong Pharmaceuticals  was previuosly developing PEGylated bovine hemoglobin-carbon monoxide for the potential iv treatment of cardiovascular disorders, beta-thalassemia, cerebral ischemia including cystic fibrosis and prevention of delayed graft function  following kidney transplantation  [&lt;ulink linkID="1648510" linkType="Reference"&gt;1648510&lt;/ulink&gt;], [&lt;ulink linkID="1676802" linkType="Reference"&gt;1676802&lt;/ulink&gt;]. In April 2015,  the program was  being evaluated for the treatment of beta-thalassemia in international trials [&lt;ulink linkID="1648510" linkType="Reference"&gt;1648510&lt;/ulink&gt;]. In September 2015, a phase II/III trial  for delayed graft function  following kidney transplantation was initiated; in October 2016, the  trial was completed [&lt;ulink linkID="1676802" linkType="Reference"&gt;1676802&lt;/ulink&gt;]. In January 2015, a phase II trial in cerebral ischemia was initiated. In October 2016, the trial was completed [&lt;ulink linkID="1623724" linkType="Reference"&gt;1623724&lt;/ulink&gt;].  However, no further development has since been reported.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In January 2015, the US FDA granted the product Orphan designation for the treatment of comorbidities associated with sickle cell disease [&lt;ulink linkID="1627683" linkType="Reference"&gt;1627683&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Leg ulcers&lt;/subtitle&gt;In May 2017, a phase II trial was planned for leg ulcers secondary to ischemia. At that time, phase I studies in healthy volunteers and patients with stable sickle cell disease  had been completed [&lt;ulink linkID="1923076" linkType="Reference"&gt;1923076&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Sickle cell anemia&lt;/subtitle&gt;In February 2016, a multicenter, single-blind, randomized, parallelÂ assignment, interventional phase II trial (&lt;ulink linkID="252474" linkType="Protocol"&gt;NCT02672540&lt;/ulink&gt;; SGSC-002) was planned to be initiated in patients (expected n = 30) with sickle cell disease to assess the safety and effect of SANGUINATE. At that time, the trial was expected to complete in September 2017. In August 2016, the trial was initiated in Colombia, Panama, Honduras and Dominican Republic. In May 2017, the trial was completed [&lt;ulink linkID="1733676" linkType="Reference"&gt;1733676&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, an open-label, non-randomized, parallel assignment, repeated-dose, dose-escalation, safety/efficacy, phase II study (&lt;ulink linkID="245437" linkType="Protocol"&gt;NCT02600390&lt;/ulink&gt;; SGSC-009) was planned to be initiated in January 2016, in Dominican Republic and Panama, in patients (expected n = 10) with sickle cell anemia. At that time, the study was expected to complete in January 2017.  In February 2017, the trial was completed [&lt;ulink linkID="1715276" linkType="Reference"&gt;1715276&lt;/ulink&gt;]. In June 2017, clinical data from 10 patients were presented at the 22nd EHA Annual Congress in Madrid, Spain. Overall, infusions of PEG-COHb were well-tolerated (qw). Of 10 patients, 2 patients had treatment-emergent adverse events (TEAEs; mild pyrexia, moderate worsening anemia) considered to be related to study drug. At most time points, total venous clinical severity score were slightly decreased, indicated slight improvement in vascular status. In cohort 1 and 2, serious adverse events (SAEs) were reported in 0 and 1 patient, respectively; patients with SAEs were 0 and 1, respectively; patients with moderate or severe TEAEs and treatment-related TEAEs were 2 and 3 and 1 and 1 patients, respectively. There were no reports of AEs that lead to withdrawn and deaths observed in either cohort [&lt;ulink linkID="1939421" linkType="Reference"&gt;1939421&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April  2015, a double-blind, placebo-controlled, single dose, parallel assignment, randomized, phase II study (&lt;ulink linkID="226423" linkType="Protocol"&gt;NCT02411708&lt;/ulink&gt;; SGSC-005) was planned to be initiated later that month, in the US,   to assess the safety and efficacy of Sanguinate  in adults (expected n = 24) with sickle cell anemia with vaso-occlusive crisis. At that time, the study was expected to complete in April 2016. In July 2015, the trial was initiated  in the US [&lt;ulink linkID="1649717" linkType="Reference"&gt;1649717&lt;/ulink&gt;]. In May 2017, preliminary data from the trial were presented at the 11th annual symposium of the Foundation for Sickle Cell Disease Research (FSCDR) in Fort Lauderdale, Fla. Data demonstrated that the drug reduced number of abnormally shaped red blood cells  by returning them to their normal morphology in patients. The whole blood samples from 10 patients were collected prior to drug infusion and 72 hours post-infusion, the effect of drug was observed within hours of infusion, and sustained even at the 72 h sampling, as a sign of an extended duration of effect [&lt;ulink linkID="1923076" linkType="Reference"&gt;1923076&lt;/ulink&gt;]. In December 2017, enrollment was completed, with the inclusion of 24 patients; at that time, data from all patients was expected to be available in the first half of 2018. Earlier that month, preliminary results from a subset of patients were presented at the 59 Annual Meeting &amp;amp; Exposition of the American Society of Hematology (ASH) in Atlanta, GA [&lt;ulink linkID="1991336" linkType="Reference"&gt;1991336&lt;/ulink&gt;]. Further data were presented at the same conference. Global RBC population in 10/16 PEG-COHb treated patients demonstrated increased circularity and decreased symmetry consistent with unsickling observed in ex vivo experiments. Of 14 PEG-COHb treated participants, 8 exhibited 40% or greater decrease in pain scores and increased RBC circularity between pre-infusion and time for readiness of discharge to 0 of 7 participants in saline cohort (p = 0.02) [&lt;ulink linkID="1988987" linkType="Reference"&gt;1988987&lt;/ulink&gt;]. In December 2017, the trial was completed [&lt;ulink linkID="1649717" linkType="Reference"&gt;1649717&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, an open-label, phase I/II study (&lt;ulink linkID="259451" linkType="Protocol"&gt;NCT02754999&lt;/ulink&gt;; SGHY-001) of the drug in patients (expected n = 10) with acute severe anemia, was to begin later that month in the US. The study was to complete in March 2017. In June 2016, the study was initiated [&lt;ulink linkID="1763755" linkType="Reference"&gt;1763755&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2013, data from a single-center, single-blind, placebo-controlled, single-dose, phase I study of Sanguinate in healthy subjects (n = 24) were presented at the Joint Conference of the International Federation of Artificial Organs and the Japan Society of Artificial Organs held inÂ Yokohama, Japan during Â September 27 to 29, 2013. Three dose levels of the drug (80, 120, and 160 mg/kg) were administered  to three groups (each group included 8 subjects), and the drug was found to be safe and well tolerated [&lt;ulink linkID="1484159" linkType="Reference"&gt;1484159&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2013, the drug was presented at 41st Sickle Cell Disease Association of America convention in Linthicum, MD. At that time, phase II trials for sickle cell anemia was planned [&lt;ulink linkID="1481691" linkType="Reference"&gt;1481691&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013, an open-label, randomized, safety and efficacy  phase I trial (&lt;ulink linkID="129676" linkType="Protocol"&gt;NCT01848925&lt;/ulink&gt;; SGSC-003) of Sanguinate at two doses levels versus hydroxyurea was planned to initiate in May 2013 in Colombia and Panama, in sickle cell disease patients (expected n = 24). At that time, the trial was expected to complete by November 2013. In May 2013, the trial was initiated in Colombia. At that time, patient recruitment was not yet initiated in Panama [&lt;ulink linkID="1439514" linkType="Reference"&gt;1439514&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013, a randomized, single-blind phase I trial (&lt;ulink linkID="127690" linkType="Protocol"&gt;NCT01847222&lt;/ulink&gt;; SGHV-005) was planned to initiate in May 2013 in healthy volunteers (expected n = 8) in Israel. At that time, the trial was expected to complete in October 2013; in August 2013, the trial was initiated. By January 2015, the trial had been terminated due to completion of competing study [&lt;ulink linkID="1438138" linkType="Reference"&gt;1438138&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2011, phase I and II studies were expected to begin later that year [&lt;ulink linkID="1163415" linkType="Reference"&gt;1163415&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2011, an open-label, unblinded, randomized, single-dose, phase I trial (&lt;ulink linkID="78178" linkType="Protocol"&gt;NCT01374165&lt;/ulink&gt;; SCIL-SANG-001) of the safety and pharmacokinetics of Sanguinate versus Lactated Ringer's was planned to start in sickle-cell disease patients (expected n= 15) in Israel in August 2011. The trial would assess two doses of Sanguinate, administered by iv infusion. At that time the  trial was estimated to complete in March 2012. In July 2012, the trial was expected to initiate in August 2012 [&lt;ulink linkID="1208558" linkType="Reference"&gt;1208558&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Kidney transplant rejection&lt;/subtitle&gt;In July 2015, a randomized, double-blind, placebo-controlled, prospective, multicenter, phase II/III trial (&lt;ulink linkID="234056" linkType="Protocol"&gt;NCT02490202&lt;/ulink&gt;; SGTP-002) was planned to be initiated to evaluate the safety and efficacy of Sanguinate for reduction of delayed graft function in recipients of a donation after brain death kidney transplant (expected n = 60). At that time, the trial was expected to complete in May 2016. In September 2015, the trial was initiated in the US. In October 2016, the trial was completed [&lt;ulink linkID="1676802" linkType="Reference"&gt;1676802&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, an open-label, single arm,  phase Ib trial (&lt;ulink linkID="228688" linkType="Protocol"&gt;NCT02437422&lt;/ulink&gt;; SGTP-001) was planned to  be initiated in the US, in  patients (expected n = 10) with end stage renal disease  , to assess the safety and efficacy of  Sanguinate. At that time, the trial was expected to complete in February 2016. In July 2015, the trial was initiated  in the US [&lt;ulink linkID="1660500" linkType="Reference"&gt;1660500&lt;/ulink&gt;]. In April 2017, clinical data  were presented at the 2017 American Transplant Congress in Chicago, IL. A total of five patients enrolled at the time sponsor stopped the study. For Sanguinate, the mean value of Cmax was 4.6 mg/ml, Tmax was 3.1 h, AUC was 159.4 mg.h/ml and t1/2 was 27.2 h. On day 8, a patient withdrew consent after a Sanguinate infusion. Throughout the study period, development of new anti-HLA antibodies after Sanguinate infusion was not observed. Adverse events reported were gastrointestinal, hematologic, musculoskeletal, neurologic, elevated troponin, and chest pain and worsening hypertension [&lt;ulink linkID="1954400" linkType="Reference"&gt;1954400&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Brain ischemia&lt;/subtitle&gt;In January 2015, a phase II trial in cerebral ischemia was initiated [&lt;ulink linkID="1623724" linkType="Reference"&gt;1623724&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2014, an open-label, single group assignment, single dose escalating, phase II study (&lt;ulink linkID="219020" linkType="Protocol"&gt;NCT02323685&lt;/ulink&gt;; SGCI-002) was planned to be initiated in December 2014,  to assess the safety and efficacy of  the drug in patients  (expected n = 12) with cerebral ischemia in the US. At that time, the study was  expected to complete in February 2016. In January 2015, the trial was initiated.  In October 2016, the trial was completed  [&lt;ulink linkID="1623724" linkType="Reference"&gt;1623724&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;OTHER STUDIES&lt;/subtitle&gt;In May 2015, clinical data were presented from 5 patients at the 51st ASCO meeting in Chicago, IL. Overall, PEG-HbCO was efficacious in patients with severe anemia who were unable to receive blood transfusions [&lt;ulink linkID="1665415" linkType="Reference"&gt;1665415&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In December 2017, in vivo data were presented at 59th ASH Annual Meeting and Exposition in Atlanta, GA. In study rats, compared to sham and LPS groups, sanguinate group restored mean arterial pressure and blood level immediately. In study rats treatment with sanguinate group improved tissue oxygenation, while sham and LPS groups remained hypoxic [&lt;ulink linkID="1988910" linkType="Reference"&gt;1988910&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2017, vitro data were presented at the 31st Annual North American Cystic Fibrosis Conference in Indianapolis, IN. In human and murine CF macrophages, sanguinatetm was found to be potent dose-dependent inducer of the heme-oxygenase (HO)-1 protein, increased CF HO-1 levels to those observed in non-CF cells. On both wild type and CF macrophages-challenged with Pseudomonas aeruginosa- lipopolysaccharide (PA-LPS) or alive PA, treatment with sanguinatetm (2mg/ml) showed anti-inflammatory effect, as demonstrated by decreased expression of pro-inflammatory cytokines (IL-6, TNF-alpha and CXCL1) [&lt;ulink linkID="1985950" linkType="Reference"&gt;1985950&lt;/ulink&gt;]. Â &lt;/para&gt;&lt;para&gt;In April 2015, in vitro data were presented at the 9th Annual Sickle Cell Disease Research &amp;amp; Educational Symposium and 38th National Sickle Cell DiseaseÂ ScientificÂ Meeting inÂ Hollywood, FL. Data demonstrated that the drug rapidly reversed sickling of human RBCs in an in vitro model and  returned the RBCs to a more normal, morphologic shape. The drug also down-regulated the inflammatory response in blood samples from sickle cell disease patients [&lt;ulink linkID="1650560" linkType="Reference"&gt;1650560&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="303">Sickle cell anemia</Indication><StatusDate>2016-08-31T00:00:00.000Z</StatusDate><Source id="1733676" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="HN">Honduras</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="303">Sickle cell anemia</Indication><StatusDate>2016-08-31T00:00:00.000Z</StatusDate><Source id="1733676" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="PA">Panama</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3096">Leg ulcer</Indication><StatusDate>2017-02-27T00:00:00.000Z</StatusDate><Source id="1715276" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="PA">Panama</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="303">Sickle cell anemia</Indication><StatusDate>2016-08-31T00:00:00.000Z</StatusDate><Source id="1733676" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="DO">Dominican Republic</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="303">Sickle cell anemia</Indication><StatusDate>2016-08-31T00:00:00.000Z</StatusDate><Source id="1733676" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="DO">Dominican Republic</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3096">Leg ulcer</Indication><StatusDate>2017-02-27T00:00:00.000Z</StatusDate><Source id="1715276" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="303">Sickle cell anemia</Indication><StatusDate>2015-07-01T00:00:00.000Z</StatusDate><Source id="1649717" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="748">Injury</Indication><StatusDate>2016-07-06T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate>2012-04-14T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="303">Sickle cell anemia</Indication><StatusDate>2016-07-06T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2018-04-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate>2016-07-06T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="748">Injury</Indication><StatusDate>2012-04-14T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2369">Beta thalassemia</Indication><StatusDate>2016-10-08T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1636">Brain ischemia</Indication><StatusDate>2016-06-13T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate>2013-04-30T00:00:00.000Z</StatusDate><Source id="1438138" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="748">Injury</Indication><StatusDate>2013-04-30T00:00:00.000Z</StatusDate><Source id="1438138" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="303">Sickle cell anemia</Indication><StatusDate>2011-05-31T00:00:00.000Z</StatusDate><Source id="1208558" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="303">Sickle cell anemia</Indication><StatusDate>2013-04-23T00:00:00.000Z</StatusDate><Source id="1439514" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1636">Brain ischemia</Indication><StatusDate>2014-11-12T00:00:00.000Z</StatusDate><Source id="1623724" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="303">Sickle cell anemia</Indication><StatusDate>2015-01-15T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2015-04-08T00:00:00.000Z</StatusDate><Source id="1648510" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="303">Sickle cell anemia</Indication><StatusDate>2013-05-31T00:00:00.000Z</StatusDate><Source id="1439514" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="PA">Panama</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="303">Sickle cell anemia</Indication><StatusDate>2013-04-23T00:00:00.000Z</StatusDate><Source id="1439514" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="303">Sickle cell anemia</Indication><StatusDate>2013-08-30T00:00:00.000Z</StatusDate><Source id="1438138" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate>2013-08-30T00:00:00.000Z</StatusDate><Source id="1438138" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="748">Injury</Indication><StatusDate>2013-08-30T00:00:00.000Z</StatusDate><Source id="1438138" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="2369">Beta thalassemia</Indication><StatusDate>2015-04-08T00:00:00.000Z</StatusDate><Source id="1648510" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2015-09-21T00:00:00.000Z</StatusDate><Source id="1676802" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1636">Brain ischemia</Indication><StatusDate>2015-01-13T00:00:00.000Z</StatusDate><Source id="1623724" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="748">Injury</Indication><StatusDate>2010-10-14T00:00:00.000Z</StatusDate><Source id="1139582" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate>2010-10-14T00:00:00.000Z</StatusDate><Source id="1139582" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30600">Prolong Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3096">Leg ulcer</Indication><StatusDate>2015-04-08T00:00:00.000Z</StatusDate><Source id="1648510" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="30600">Prolong Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="303">Sickle cell anemia</Indication><AwardedIndication>Treatment of the comorbidities associated with Sickle Cell Disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-01-15T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="30600">Prolong Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="303">Sickle cell anemia</Indication><AwardedIndication>Treatment of acute painful sickling crises in patients with sickle cell disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2010-10-21T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="30600">Prolong Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="303">Sickle cell anemia</Indication><AwardedIndication>Treatment of sickle cell disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2009-11-26T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="30600">Prolong Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="303">Sickle cell anemia</Indication><AwardedIndication>Treatment of sickle cell disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2009-10-07T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00905"><Name>Hemoglobin</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=1649717" linkType="reference" linkID="1649717"&gt;1649717&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2059941" linkType="reference" linkID="2059941"&gt;2059941&lt;/ulink&gt;]							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="2851322" number="WO-2014205077" title="Hemoglobin compositions"/><PatentFamily id="3130525" number="WO-2016022554" title="Hemoglobin compositions"/><PatentFamily id="871297" number="WO-2010144629" title="Hemoglobin compositions"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Prolong Pharmaceuticals Inc" id="30600"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>